Results · Apr-Jun 2026 · filed 14 Aug 2026
ANG Lifesciences India Q1 FY27 results
Sales fell 38% to ₹15.3 crore from ₹24.6 crore in Apr-Jun 2025.
Operating profit fell 403% to −₹2 crore, an operating margin of −12.8% (down 15.4 points from a year ago).
The net loss widened to ₹4.2 crore from ₹2 crore.
Against Jan-Mar 2026: sales −35%, loss widens.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 15.3 | 24.6 | −38% |
| Operating profit (EBITDA) | -2.0 | 0.6 | −403% |
| Operating margin | −12.8% | 2.6% | −15.4 pts |
| Net profit | -4.2 | -2.0 | loss widens |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 8 quarters
Filings that week
- 14 Aug 2026Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 30.06.2026 Under Regulation 33 Of The SEBI (LODR) Regulations, 20
- 14 Aug 2026Board Meeting Outcome for Board Meeting Outcome For Submission Of Standalone And Consolidated Unaudited Financial Results For The Quarter Ended On 30.06.2026 Un
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.